EUVIMEDEUVIMED entdecken
Crossref

Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery

Hiroshi Kamiyama, Masayuki Miyano, Daisuke Ito, Takayuki Kimura, Koji Hagiwara, Hiroyuki Kogai, Yosuke Kaburagi, Yoshihiko Kotake, Yasutaka Takase

Chemical Biology & Drug Design · 2023-03 · 101 (3) · 727-739

DOI: 10.1111/cbdd.14176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 25.11.2022. Verfasst von Hiroshi Kamiyama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan. Hauptthemen laut MEDLINE: Aldehyde Oxidoreductases, Phosphodiesterase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The identification of biologically active target compounds and their binding proteins is important in mechanism‐of‐action studies for drug development. Additionally, the newly discovered binding proteins provide unforeseen ideas for novel drug discovery and for subsequent structural transformation to improve target specificity. Based on the lead and final candidate compounds related to the type 5 phosphodiesterase (PDE5) inhibitor E4021, we designed chemical probes and identified their target proteins by the affinity chromatography approach. Aldehyde dehydrogenase family 1 member A3 (ALDH1A3), currently reported as a cancer stem cell target, was clearly isolated as a binding protein of the lead ‘immature’ inhibitor probe against PDE5. In the early derivatization to the closely related structure, Compound 5 (ER‐001135935) was found to significantly inhibit ALDH1A3 activity. The discovery process of a novel ALDH1A3‐selective inhibitor with affinity‐based binder identification is described, and the impact of this identification method on novel drug discovery is discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aldehyde OxidoreductasesPhosphodiesterase InhibitorsNeoplastic Stem CellsDrug Discovery

Stichwörter der Autor:innen

ALDH1A3-selective inhibitorPDE5affinity chromatographychemical probedrug target discovery

Substanzen

Aldehyde OxidoreductasesPhosphodiesterase Inhibitors

Autor:innen und Institutionen

  • Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.

Zitieren

APA

Kamiyama, H., Miyano, M., Ito, D., Kimura, T., Hagiwara, K., Kogai, H., Kaburagi, Y., Kotake, Y., & Takase, Y. (2023). Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery. Chemical Biology & Drug Design, 101(3), 727-739. https://doi.org/10.1111/cbdd.14176

Vancouver

Kamiyama H, Miyano M, Ito D, Kimura T, Hagiwara K, Kogai H, et al. Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery. Chemical Biology & Drug Design. 2023;101(3):727-739. doi:10.1111/cbdd.14176

BibTeX
@article{Kamiyama2023,
  author = {Kamiyama, Hiroshi and Miyano, Masayuki and Ito, Daisuke and Kimura, Takayuki and Hagiwara, Koji and Kogai, Hiroyuki and Kaburagi, Yosuke and Kotake, Yoshihiko and Takase, Yasutaka},
  title = {Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  volume = {101},
  number = {3},
  pages = {727--739},
  doi = {10.1111/cbdd.14176}
}
Kostenlos starten →